-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzinova launches global Phase II trial of Alzheimer’s vaccine candidate ALZ-101

PUBT·09/22/2026 14:03:56
Listen to the news
Alzinova launches global Phase II trial of Alzheimer’s vaccine candidate ALZ-101
  • GU Ventures portfolio company Alzinova began operational start-up of a global Phase II trial for Alzheimer’s vaccine candidate ALZ-101.
  • Planned enrollment of about 120 early Alzheimer’s patients; first participants targeted around the 2026/2027 year-end.
  • Alzinova launched a rights issue of about SEK 51 million to fund ALZ-101 development and execution of the Phase II program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.